{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:59:46Z","timestamp":1790686786449,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01705-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:29:46Z","timestamp":1789666186000},"page":"1429-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Pharmacokinetics and Disposition of Imrecoxib"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-1807","authenticated-orcid":false,"given":"Shengnan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-7891","authenticated-orcid":false,"suffix":"III","given":"Marlon C.","family":"Mallillin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-0213","authenticated-orcid":false,"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-1471","authenticated-orcid":false,"given":"Neal M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"25","key":"1705_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232\u20135. https:\/\/doi.org\/10.1038\/newbio231232a0.","journal-title":"Nat New Biol"},{"issue":"6","key":"1705_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJM200108093450607","volume":"345","author":"GA FitzGerald","year":"2001","unstructured":"FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433\u201342. https:\/\/doi.org\/10.1056\/NEJM200108093450607.","journal-title":"N Engl J Med"},{"issue":"11","key":"1705_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa050493.","journal-title":"N Engl J Med"},{"issue":"1","key":"1705_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI27291","volume":"116","author":"T Grosser","year":"2006","unstructured":"Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Investig. 2006;116(1):4\u201315. https:\/\/doi.org\/10.1172\/JCI27291.","journal-title":"J Clin Investig"},{"issue":"8","key":"1705_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1517\/14656566.2013.783568","volume":"14","author":"I Atukorala","year":"2013","unstructured":"Atukorala I, Hunter DJ. Valdecoxib: the rise and fall of a COX-2 inhibitor. Expert Opin Pharmacother. 2013;14(8):1077\u201386. https:\/\/doi.org\/10.1517\/14656566.2013.783568.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1705_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.therap.2018.02.004","volume":"76","author":"S Babai","year":"2021","unstructured":"Babai S, Auclert L, Le-Louet H. Safety data and withdrawal of hepatotoxic drugs. Therapies. 2021;76(6):715\u201323. https:\/\/doi.org\/10.1016\/j.therap.2018.02.004.","journal-title":"Therapies"},{"issue":"3","key":"1705_CR7","first-page":"223","volume":"21","author":"Z Guo","year":"2012","unstructured":"Guo Z. Discovery of imrecoxib (\u56fd\u5bb61\u7c7b\u65b0\u836f\u827e\u745e\u6614\u5e03\u7684\u7814\u5236). Chin J New Drugs. 2012;21(3):223\u201330.","journal-title":"Chin J New Drugs"},{"issue":"7","key":"1705_CR8","first-page":"927","volume":"25","author":"XH Chen","year":"2004","unstructured":"Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004;25(7):927\u201331.","journal-title":"Acta Pharmacol Sin"},{"issue":"22","key":"1705_CR9","first-page":"1740","volume":"46","author":"J Huang","year":"2011","unstructured":"Huang J, Gu J, Pan Y, Zhang F, Sun L, Wu D, et al. A multicenter, double-blind and randomized controlled phase II trial of imrecoxib in treatment of knee osteoarthritis (\u827e\u745e\u6614\u5e03\u7247\u6cbb\u7597\u819d\u9aa8\u5173\u8282\u708e\u7684\u2161\u671f\u591a\u4e2d\u5fc3\u968f\u673a\u53cc\u76f2\u4e34\u5e8a\u8bd5\u9a8c). Chin Pharm J. 2011;46(22):1740\u20135.","journal-title":"Chin Pharm J"},{"issue":"3","key":"1705_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3969\/j.issn.1673-8705.2014.03.008","volume":"8","author":"D Xu","year":"2014","unstructured":"Xu D, Zhang F, Gu J, Xu J, Tao Y, Zhang F, et al. A multicenter double-blind and randomized controlled phase III trial of imrecoxib in the treatment of knee osteoarthritis (\u827e\u745e\u6614\u5e03\u6cbb\u7597\u819d\u9aa8\u5173\u8282\u708e\u7684\u2162\u671f\u591a\u4e2d\u5fc3\u968f\u673a\u53cc\u76f2\u4e34\u5e8a\u8bd5\u9a8c). Chin J Allergy & Clin Immunol. 2014;8(3):205\u201310. https:\/\/doi.org\/10.3969\/j.issn.1673-8705.2014.03.008.","journal-title":"Chin J Allergy & Clin Immunol"},{"key":"1705_CR11","unstructured":"Huang J. Phase I clinical pharmacokinetic study of imrecoxib by LC\/MS\/MS method (\u6db2\u76f8\u8272\u8c31\u2014\u4e32\u8054\u8d28\u8c31\u6cd5\u7814\u7a76\u827e\u745e\u6614\u5e03I\u671f\u4e34\u5e8a\u836f\u4ee3\u52a8\u529b\u5b66) [Master\u2019s thesis]. Shenyang Pharmaceutical University; 2005."},{"key":"1705_CR12","doi-asserted-by":"publisher","unstructured":"Li Q. Pharmacokinetic Study of Imrecoxib (\u827e\u745e\u6614\u5e03\u7684\u836f\u7269\u52a8\u529b\u5b66\u7814\u7a76). Guide of China Medicine. 2012;10(18):500\u20131. https:\/\/doi.org\/10.15912\/j.cnki.gocm.2012.18.536.","DOI":"10.15912\/j.cnki.gocm.2012.18.536"},{"key":"1705_CR13","unstructured":"Hou X. Effect of hepatic impairment on the pharmacokinetics of imrecoxib and its mechanism study (\u809d\u529f\u80fd\u4e0d\u5168\u5bf9\u827e\u745e\u6614\u5e03\u836f\u52a8\u5b66\u7684\u5f71\u54cd\u53ca\u5176\u673a\u5236\u7814\u7a76) [Doctoral dissertation]. University of Chinese Academy of Sciences (Shanghai Institute of Materia Medica, Chinese Academy of Sciences); 2019."},{"issue":"10","key":"1705_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00228-019-02698-x","volume":"75","author":"Q Pei","year":"2019","unstructured":"Pei Q, Xie J, Huang J, Liu W, Yang X, Wang Y, et al. Pharmacokinetic study of imrecoxib in patients with renal insufficiency. Eur J Clin Pharmacol. 2019;75(10):1355\u201360. https:\/\/doi.org\/10.1007\/s00228-019-02698-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1705_CR15","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.2147\/DDDT.S387508","volume":"16","author":"L Yang","year":"2022","unstructured":"Yang L, Shen Q, Hu C, Wang Y, Zhu X, Shu S, et al. Comparative pharmacokinetics and safety of imrecoxib, a novel selective cyclooxygenase-2 inhibitor, in elderly healthy subjects. Drug Des Dev Ther. 2022;16:3865\u201376. https:\/\/doi.org\/10.2147\/DDDT.S387508.","journal-title":"Drug Des Dev Ther"},{"key":"1705_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105449","volume":"152","author":"Y Li","year":"2020","unstructured":"Li Y, Wang J, Huang J, Yu J, Wang Y, Tan H, et al. Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation. Eur J Pharm Sci. 2020;152:105449. https:\/\/doi.org\/10.1016\/j.ejps.2020.105449.","journal-title":"Eur J Pharm Sci"},{"key":"1705_CR17","unstructured":"Han Y. Preclinical pharmacokinetic and toxicokinetic study of imrecoxib by LC\/MS\/MS method (\u6db2\u76f8\u8272\u8c31-\u4e32\u8054\u8d28\u8c31\u6cd5\u7814\u7a76\u827e\u745e\u6614\u5e03\u4e34\u5e8a\u524d\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u6bd2\u4ee3\u52a8\u529b\u5b66) [Master\u2019s thesis]. Shenyang Pharmaceutical University; 2003."},{"issue":"9","key":"1705_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1124\/dmd.118.081182","volume":"46","author":"X Hou","year":"2018","unstructured":"Hou X, Zhou J, Yu S, Zhou L, Zhang Y, Zhong D, et al. Differences in the in vivo and in vitro metabolism of imrecoxib in humans: formation of the rate-limiting aldehyde intermediate. Drug Metab Dispos. 2018;46(9):1320\u20138. https:\/\/doi.org\/10.1124\/dmd.118.081182.","journal-title":"Drug Metab Dispos"},{"key":"1705_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jchromb.2019.05.018","volume":"1122\u20131123","author":"X Hou","year":"2019","unstructured":"Hou X, Dai X, Yang Y, Zhang Y, Zhong D, Chen X. Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci. 2019;1122\u20131123:58\u201363. https:\/\/doi.org\/10.1016\/j.jchromb.2019.05.018.","journal-title":"J Chromatogr B: Anal Technol Biomed Life Sci"},{"issue":"5","key":"1705_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/00498250600595524","volume":"36","author":"H Xu","year":"2006","unstructured":"Xu H, Zhang Y, Sun Y, Zhang P, Chu F, Guo Z, et al. Metabolism and excretion of imrecoxib in rat. Xenobiotica. 2006;36(5):441\u201355. https:\/\/doi.org\/10.3109\/00498250600595524.","journal-title":"Xenobiotica"},{"issue":"3","key":"1705_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1745-7254.2006.00265.x","volume":"27","author":"H Xu","year":"2006","unstructured":"Xu H, Xie Z, Zhang P, Sun J, Chu F, Guo Z, et al. Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib. Acta Pharmacol Sin. 2006;27(3):372\u201380. https:\/\/doi.org\/10.1111\/j.1745-7254.2006.00265.x.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"1705_CR22","first-page":"912","volume":"40","author":"Q Li","year":"2005","unstructured":"Li Q, Huang H, Dong Y, Zhong D. Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs. Acta Pharm Sin (Yao xue xue bao). 2005;40(10):912\u20135.","journal-title":"Acta Pharm Sin (Yao xue xue bao)"},{"issue":"8","key":"1705_CR23","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.bmcl.2009.02.090","volume":"19","author":"Z Feng","year":"2009","unstructured":"Feng Z, Chu F, Guo Z, Sun P. Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009;19(8):2270\u20132. https:\/\/doi.org\/10.1016\/j.bmcl.2009.02.090.","journal-title":"Bioorg Med Chem Lett"},{"key":"1705_CR24","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhang D, Song W, Ding L, Chen Y, Yang L, et al. Pharmacokinetics of imrecoxib in patients with moderate hepatic impairment (\u827e\u745e\u6614\u5e03\u7247\u5728\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\u53d7\u8bd5\u8005\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u7814\u7a76). Chin J Clin Pharmacol. 2021;37(10):1222\u20135. https:\/\/doi.org\/10.13699\/j.cnki.1001-6821.2021.10.022.","DOI":"10.13699\/j.cnki.1001-6821.2021.10.022"},{"issue":"3","key":"1705_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00228-019-02824-9","volume":"76","author":"NR Srinivas","year":"2020","unstructured":"Srinivas NR. Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients. Eur J Clin Pharmacol. 2020;76(3):469\u201371. https:\/\/doi.org\/10.1007\/s00228-019-02824-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"1705_CR26","unstructured":"U.S. Food and Drug Administration. Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing. Guidance for Industry. U.S. Food and Drug Administration; 2020."},{"issue":"12","key":"1705_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1705_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","volume":"45","author":"JO Miners","year":"1998","unstructured":"Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525\u201338. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00721.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1705_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51755-z","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang R, Li Z, Zhou J, Yang T, Yang C, et al. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019;9(1):15774. https:\/\/doi.org\/10.1038\/s41598-019-51755-z.","journal-title":"Sci Rep"},{"key":"1705_CR30","doi-asserted-by":"publisher","unstructured":"Gong Y, He W, Wang W, Zhang Z. Evaluation of the effects of imrecoxib on CYP2C9 enzyme in rats using a probe drug (\u63a2\u9488\u836f\u7269\u6cd5\u8bc4\u4ef7\u827e\u745e\u6614\u5e03\u5bf9\u5927\u9f20CYP2C9\u9176\u7684\u5f71\u54cd). Chin J Pharm. 2015;46(2):190\u20132, 219. https:\/\/doi.org\/10.16522\/j.cnki.cjph.2015.02.023.","DOI":"10.16522\/j.cnki.cjph.2015.02.023"},{"issue":"8","key":"1705_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.clinthera.2018.06.009","volume":"40","author":"C Zuo","year":"2018","unstructured":"Zuo C, Gong Y, Hou X, Zhang Y, Peng W, Zhu R, et al. Effect of fluconazole on the pharmacokinetic properties of imrecoxib, a novel NSAID: a single-center, open-label, self-controlled study in healthy Chinese male volunteers. Clin Ther. 2018;40(8):1347\u201356. https:\/\/doi.org\/10.1016\/j.clinthera.2018.06.009.","journal-title":"Clin Ther"},{"key":"1705_CR32","doi-asserted-by":"publisher","unstructured":"Wu M, Xie H, Yang N, Zhu H, Xu R, Li W, et al. Determination of plasma concentrations of imrecoxib and its two active metabolites in patients with knee osteoarthritis by liquid chromatography-tandem mass spectrometry (\u819d\u9aa8\u5173\u8282\u708e\u60a3\u8005\u53e3\u670d\u827e\u745e\u6614\u5e03\u540e\u4e3b\u8981\u6d3b\u6027\u6210\u5206\u7a33\u6001\u8840\u836f\u8c37\u6d53\u5ea6\u76d1\u6d4b). Pharm Clin Res. 2023;31(1):11\u20136. https:\/\/doi.org\/10.13664\/j.cnki.pcr.2023.01.005.","DOI":"10.13664\/j.cnki.pcr.2023.01.005"},{"issue":"3","key":"1705_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00228-019-02826-7","volume":"76","author":"Q Pei","year":"2020","unstructured":"Pei Q, Xie J, Zhang H, Yang G. Response by Pei et al. to letters regarding article, \u201cPharmacokinetic study of imrecoxib in patients with renal insufficiency.\u201d Eur J Clin Pharmacol. 2020;76(3):473\u20134. https:\/\/doi.org\/10.1007\/s00228-019-02826-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1705_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/archinte.165.2.189","volume":"165","author":"M Battistella","year":"2005","unstructured":"Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189\u201392. https:\/\/doi.org\/10.1001\/archinte.165.2.189.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1705_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cpt.1830","volume":"108","author":"KN Theken","year":"2020","unstructured":"Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191\u2013200. https:\/\/doi.org\/10.1002\/cpt.1830.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1705_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40744-023-00636-z","volume":"11","author":"H Xie","year":"2024","unstructured":"Xie H, Zhang Y, Zhu Z, Wei J, Ainiwaer G, Ge W. Plasma proteomic analysis based on 4D-DIA evaluates the clinical response to imrecoxib in the early treatment of osteoarthritis. Rheumatol Ther. 2024;11(2):269\u201383. https:\/\/doi.org\/10.1007\/s40744-023-00636-z.","journal-title":"Rheumatol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01705-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:55Z","timestamp":1790684395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01705-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01705-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Neal M. Davies is an Editorial Board member of Clinical Pharmacokinetics. Neal M. Davies was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Shengnan Zhao, Charlie Li, Marlon C. Mallillin III, and Raimar Lobenberg have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a narrative review of previously published studies and did not involve new human or animal participants.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This narrative review did not involve the recruitment of human participants.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no new datasets were generated or analysed during the preparation of this review. All data discussed are derived from the cited published sources.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No software code or custom algorithms were developed for this review.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.M.D. conceived and drafted the review. S.Z., C.L., M.C.M., R.L., and N.M.D. contributed to the literature search and data analysis, critically revised the manuscript, approved the final version, and agree to be accountable for its content.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}